| Quantifying Systemic Immunosuppression to Personalize Cancer Therapy (NCT05621837) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 2022-03-10 |
| Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer (NCT05072600) | Peking University First Hospital | 2021-12-07 |
| Neoadjuvant Toripalimab in Combination with Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects (NCT04861584) | Zhujiang Hospital | 2021-06-03 |
| Role of Hypofractionated Radiotherapy With Concurrent Gemcitabine in Treatment of Urinary Bladder Carcinoma (NCT04812145) | Assiut University | 2021-04-01 |
| Multimodal Spectroscopy to Detect Urothelial Cancer in Urine (NCT04718948) | University of Florence | 2021-01-28 |
| Patterns of Urinary Bladder Cancer in Darfur, Suda (NCT06156787) | National Center for Gastroentestinal and Liver Disease | 2020-11-01 |
| Clinicoepidimiological Study and Clinical Outcome in Patients With Urinary Bladder Cancer (NCT04525781) | Assiut University | 2020-10-01 |
| An Epidemiologic Study on PD-L1 Expression Combined With Clinical Observation in the Chinese MIUBC Patients. (NCT03433924) | AstraZeneca | 2020-05-18 |
| Neutrophils to Lymphocytes Ratio in Predicting the Response to BCG in Non-muscle Invasive Bladder Cancer (NCT05946369) | Ain Shams University | 2020-05-01 |
| Physical Rehabilitation Among Patients Undergoing Radical Cystectomy Due to Urinary Bladder Cancer (NCT03998579) | Karolinska Institutet | 2019-09-01 |
| Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors. (NCT03335059) | Medical Enterprises Ltd. | 2019-04-04 |
| Evaluation of NanoDoce® in Participants With Urothelial Carcinoma (NCT03636256) | NanOlogy, LLC | 2019-04-02 |
| Pharmacological Enhancement for Nocturnal Incontinence in Orthotopic Bladder Substitute (NCT04635566) | Mansoura University | 2019-03-01 |
| Radio-Immunotherapy Before Cystectomy in Locally Advanced Urothelial Carcinoma of the Bladder (NCT03529890) | Technical University of Munich | 2019-02-04 |
| A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study (NCT03844256) | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 2019-01-07 |
| MAGE-A4ᶜ¹º³²T for Multi-Tumor (NCT03132922) | USWM CT, LLC | 2017-05-15 |
| A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer (NCT02897765) | BioNTech US Inc. | 2016-10-01 |
| Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer (NCT02722538) | Taris Biomedical LLC | 2016-05-31 |
| Safety and Tolerability of TAR-200 mg in Subjects With Non-Muscle-Invasive Bladder Cancer (NCT02720367) | Taris Biomedical LLC | 2016-01-01 |
| Evaluation of a New Radiotracer (68Ga-NOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography (NCT02437539) | Rigshospitalet, Denmark | 2015-05-01 |
| Comparing Operative, Postoperative and Quality of Life of Patients After Salvage and Radical Cystectomy (NCT06115434) | Assiut University | 2015-01-30 |
| Evaluation of a New Radiotracer (64Cu-DOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography (NCT02139371) | Rigshospitalet, Denmark | 2014-05-01 |
| Prehabilitation to Enhance Postoperative Functional Capacity Following Radical Cystectomy (NCT01836978) | McGill University Health Centre/Research Institute of the McGill University Health Centre | 2013-06-01 |
| Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ (NCT00462488) | Sesen Bio, Inc. | 2007-03-01 |
| Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer (NCT00872495) | Lahey Clinic | 2002-09-01 |
| Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer (NCT00384891) | Medical Enterprises Europe B.V. | 2002-02-01 |